contrast-induced nephropathy
Conditions
Interventions
Low-dose dapagliflozin group (5mg) VS high-dose dapagliflozin group (10mg):In the low-dose dapagliflozin group (5mg) and the high-dose dapagliflozin group (10mg), the first and second doses of dapagli
Sponsors
Department of Cardiology, Zhongda Hospital of Southeast University Medical School
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in this trial and sign the informed consent; 2. Aged 18 to 85 years; 3. Coronary angiography is planned; 4.45ml/min/1.73m<=eGFR<=89ml/min/1.73m 5. According to the WHO (1990) standard, the diagnosis of type 2 diabetes is clear; 6. Coronary heart disease.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of hypersensitivity to contrast agents who meet the contraindications in the instructions for dapagliflozin: patients with a history of severe hypersensitivity reactions to this product; severe renal impairment (eGFR less than 30mL/min/1.73m2); end-stage renal disease (ESRD) ) or patients requiring dialysis; 2. Lactation, pregnancy; 3. Those who used dapagliflozin, contrast agents, and nephrotoxic drugs within 1 week before enrollment; 4. Acute ST-segment elevation myocardial infarction (STEMI) 5. Use of aortic balloon counterpulsation, severe cardiac insufficiency (cardiac function stage IV), severe heart valve disease, hemodynamic instability, acute heart failure, liver failure, connective tissue disease, malignant tumor, severe infectious disease Disease, cardiogenic shock in hospital, sudden cardiac death, etc. 6. Poor compliance with treatment and uncooperative examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures:The incedence of CIN;serum creatnine CystatinC HE4; | — |
Countries
China
Contacts
Public ContactYan Gaoliang
Department of Cardiology, Zhongda Hospital of Southeast University Medical School
Outcome results
None listed